tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 157 are a BUY (67.67%), 70 are a HOLD (30.17%), 5 are a SELL (2.16%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 73.49% that have a potential upside of 43.87% achieved within 313 days.
Judah Frommer’s has documented 459 price targets and ratings displayed on 47 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on BLTE, Belite Bio ADR at 14-Aug-2026.
Analyst best performing recommendations are on ACLX (ARCELLX).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 04-Sep-2024
$121
$-5.59 (-4.42%)
$101
Buy Since 11-Sep-2014
$150
$23.41 (18.49%)
$132
Hold Since 14-Nov-2021
$145
$18.41 (14.54%)
$130
Buy Since 08-Apr-2018
$138
$11.41 (9.01%)
$136
Buy Since 10-Jan-2018
$145
$18.41 (14.54%)
$135
Which stock is Judah Frommer is most bullish on?
Which stock is Judah Frommer is most reserved on?
What Year was the first public recommendation made by Judah Frommer?
